Results 181 to 190 of about 2,098,321 (310)

Sociodemographic and Health Behaviour of Frequent, Avoidable Emergency Department Users in Ontario, Canada: A Population-based Descriptive Study. [PDF]

West J Emerg Med
Thompson C, Watson T, Schull MJ, Gronsbell J, Rosella LC.   +4 more
europepmc   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Associations between adolescents' oral health and health literacy, gender and family affluence: perspective of the Health Behaviour in School-aged Children study data from Slovakia and Poland. [PDF]

Front Public Health
Glińska KK, Kizek P, Madarasova Geckova A, Boberova Z, Dzielska A, Kleszczewska D, Sigmund E, Jurkova V, Kopcakova J.   +8 more
europepmc   +1 more source

Risk and protective factors for health behaviour in adolescence in Europe. [PDF]

Sci Rep, 2023
Zsakai A, Ratz-Sulyok FZ, Koronczai B, Varro P, Toth E, Szarvas S, Tauber T, Karkus Z, Molnar K.   +8 more
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Deploying the Substitutive and Complementary Approaches to Enhance Predictions of Health Behaviour in Health Economics: A Quantitative Study. [PDF]

Healthcare (Basel)
Broekharst DSE, Bloem S, Groenland EAG, Jeurissen PPT, van Agthoven M.   +4 more
europepmc   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Factors influencing dental care services utilization in India using Andersen health behaviour model: a systematic review. [PDF]

BMC Health Serv Res
Negi S, Mathur A, Udhaya E, Rani N, Mehta V.   +4 more
europepmc   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial. [PDF]

Mult Scler
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Meyer B, Asendorf T, Temmes H, van de Loo M, Gold SM, Schubert C, Stürner KH, Warnke C, Schmidt S, Friede T, Heesen C, POWER@MS1 study group.   +15 more
europepmc   +1 more source